These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 7551323

  • 1. Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum.
    Elias D, Farace F, Triebel F, Hattchouel JM, Pignon JP, Lecesne A, Rougier P, Lasser P, Duvillard P, Escudier B.
    J Am Coll Surg; 1995 Oct; 181(4):303-10. PubMed ID: 7551323
    [Abstract] [Full Text] [Related]

  • 2. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F, Piacentini MG, Franciosi C, Caprotti R, De Fina S, Cesana G, Uggeri F, Conti M, Uggeri F.
    Hepatogastroenterology; 2004 Oct; 51(60):1872-6. PubMed ID: 15532847
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [Abstract] [Full Text] [Related]

  • 5. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
    Kolitz JE, Wong GY, Welte K, Merluzzi VJ, Engert A, Bialas T, Polivka A, Bradley EC, Konrad M, Gnecco C.
    J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
    [Abstract] [Full Text] [Related]

  • 6. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.
    West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK.
    N Engl J Med; 1987 Apr 09; 316(15):898-905. PubMed ID: 3493433
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Interleukin-2 therapy in relapsed acute myelogenous leukemia.
    Meloni G, Vignetti M, Pogliani E, Invernizzi R, Allione B, Mirto S, Sica S, Leoni F, Selleri C, Mandelli F.
    Cancer J Sci Am; 1997 Dec 09; 3 Suppl 1():S43-7. PubMed ID: 9457393
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
    Lorenz M, Staib-Sebler E, Gog C, Proschek D, Jauch KW, Ridwelski K, Hohenberger W, Gassel HJ, Lehmann U, Vestweber KH, Padberg W, Zamzow K, Müller HH.
    Zentralbl Chir; 2003 Feb 09; 128(2):87-94. PubMed ID: 12632273
    [Abstract] [Full Text] [Related]

  • 11. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R, Rosenberg SA.
    J Immunol; 1985 Dec 09; 135(6):4273-80. PubMed ID: 3877766
    [Abstract] [Full Text] [Related]

  • 12. Simultaneous percutaneous right portal vein embolization and left liver tumor radiofrequency ablation prior to a major right hepatic resection for bilateral colorectal metastases.
    Elias D, Santoro R, Ouellet JF, Osmak L, de Baere T, Roche A.
    Hepatogastroenterology; 2004 Dec 09; 51(60):1788-91. PubMed ID: 15532827
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis.
    Gardini A, Ercolani G, Riccobon A, Ravaioli M, Ridolfi L, Flamini E, Ridolfi R, Grazi GL, Cavallari A, Amadori D.
    J Surg Oncol; 2004 Jul 15; 87(1):46-52. PubMed ID: 15221919
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.
    Tamura T, Sasaki Y, Shinkai T, Eguchi K, Sakurai M, Fujiwara Y, Nakagawa K, Minato K, Bungo M, Saijo N.
    Cancer Res; 1989 Feb 01; 49(3):730-5. PubMed ID: 2783385
    [Abstract] [Full Text] [Related]

  • 15. Clinical application of continuous infusion of recombinant interleukin-2.
    West WH.
    Eur J Cancer Clin Oncol; 1989 Feb 01; 25 Suppl 3():S11-5. PubMed ID: 2627985
    [Abstract] [Full Text] [Related]

  • 16. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
    Dutcher JP, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F, Sosman J, Lotze M, Gordon M, Logan T, Mier J.
    Cancer J Sci Am; 1997 Dec 01; 3 Suppl 1():S73-8. PubMed ID: 9457399
    [Abstract] [Full Text] [Related]

  • 17. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K, Margolin K, Champlin R, Forman S.
    Cancer J Sci Am; 1997 Dec 01; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [Abstract] [Full Text] [Related]

  • 18. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
    Lauria F, Raspadori D, Ventura MA, Rondelli D, Zinzani PL, Gherlinzoni F, Miggiano MC, Fiacchini M, Rosti G, Rizzi S, Tura S.
    Bone Marrow Transplant; 1996 Jul 01; 18(1):79-85. PubMed ID: 8831999
    [Abstract] [Full Text] [Related]

  • 19. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF, Aramendía JM, Alonso G, Foncillas JG, Brugarolas A.
    Rev Med Univ Navarra; 1996 Jul 01; 40(3):6-12. PubMed ID: 9499820
    [Abstract] [Full Text] [Related]

  • 20. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
    Weiner LM, Colarusso P, Goldberg M, Dresler C, Coia LR.
    Semin Oncol; 1997 Dec 01; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.